J Am Heart Assoc:补充维生素D对中心血压参数有何影响?

2017-11-20 何娜 环球医学

有报道称,缺乏维生素D的人更有可能患高血压、II型糖尿病以及高血脂。2017年10月,发表在《J Am Heart Assoc》的一项双盲、安慰剂对照亚研究调查了每月、高剂量、长期补充维生素D对中心血压(BP)参数的影响。结果表明,每月高剂量补充维生素D持续1年可降低缺乏维生素D成人的中心BP参数,但不能降低总样本的参数。

有报道称,缺乏维生素D的人更有可能患高血压、II型糖尿病以及高血脂。2017年10月,发表在《J Am Heart Assoc》的一项双盲、安慰剂对照亚研究调查了每月、高剂量、长期补充维生素D对中心血压(BP)参数的影响。结果表明,每月高剂量补充维生素D持续1年可降低缺乏维生素D成人的中心BP参数,但不能降低总样本的参数。

背景:每月、高剂量、长期补充维生素D对中心BP参数的影响尚不清楚。

方法和结果:该双盲、安慰剂对照亚试验共招募517例成人(58%为男性,年龄在50~84岁)。受试者被分配至接受1.1年(中位;范围:0.9~1.5年),或(1)维生素D3 200000 IU(初始剂量),随后1个月后每月100000‐IU剂量(n=256)或(2)每月安慰剂(n=261)。基线(n=517)和随访(n=380)期,分别测量主动脉BP波形和血液动力学参数。维生素D组的25羟基维生素D从基线66 nmol/L(SD:24)平均延长至随访期的122 nmol/L(SD:42),安慰剂组没有变化。尽管总样本中的血液动力学参数发生较小、不显着的变化(主要结局),研究者观察到150例基线缺乏维生素D(<50 nmol/L)的受试者发生一致的获益变化。在该亚组中,维生素D组(n=71)与安慰剂组(n=79)相比,上臂收缩压平均变化为?5.3 mm Hg(95%置信区间[CI],?11.8~1.3)(P=0.11),上臂舒张压平均变化为?2.8 mm Hg(95% CI,?6.2~0.7)(P=0.12),主动脉收缩压平均变化为?7.5 mm Hg(95% CI,?14.4~?0.6)(P=0.03),反射波增强指数平均变化为?5.7 mm Hg(95% CI,?10.8~?0.6)(P=0.03),脉搏波传播速度平均变化为?0.3 m/s(95% CI,?0.6~?0.1)(P=0.02),储层压力峰值平均变化为?8.6 mm Hg(95% CI,?15.4~?1.9)(P=0.01),向后压力振幅平均变化为?3.6 mm Hg(95% CI,?6.3~?0.8)(P=0.01)。

结论:每月高剂量补充维生素D1年可降低缺乏维生素D的成人的中心BP参数,但不能降低总样本的参数。

临床试验注册:URL: http://www.anzctr.org.au。唯一编号:ACTRN12611000402943。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655618, encodeId=c50d165561878, content=<a href='/topic/show?id=93e12218000' target=_blank style='color:#2F92EE;'>#中心血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22180, encryptionId=93e12218000, topicName=中心血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7724759256, createdName=Homburg, createdTime=Thu Dec 28 13:24:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275733, encodeId=ae422e5733d9, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 13:01:53 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356577, encodeId=0a4f13565e715, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 22 06:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562749, encodeId=97641562e49d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Nov 22 06:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262870, encodeId=f1ee2628e09f, content=所以缺啥补啥, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Mon Nov 20 16:17:09 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655618, encodeId=c50d165561878, content=<a href='/topic/show?id=93e12218000' target=_blank style='color:#2F92EE;'>#中心血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22180, encryptionId=93e12218000, topicName=中心血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7724759256, createdName=Homburg, createdTime=Thu Dec 28 13:24:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275733, encodeId=ae422e5733d9, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 13:01:53 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356577, encodeId=0a4f13565e715, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 22 06:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562749, encodeId=97641562e49d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Nov 22 06:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262870, encodeId=f1ee2628e09f, content=所以缺啥补啥, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Mon Nov 20 16:17:09 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
    2018-01-05 1dd8c52fm63(暂无匿称)

    学习学习.继续关注

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1655618, encodeId=c50d165561878, content=<a href='/topic/show?id=93e12218000' target=_blank style='color:#2F92EE;'>#中心血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22180, encryptionId=93e12218000, topicName=中心血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7724759256, createdName=Homburg, createdTime=Thu Dec 28 13:24:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275733, encodeId=ae422e5733d9, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 13:01:53 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356577, encodeId=0a4f13565e715, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 22 06:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562749, encodeId=97641562e49d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Nov 22 06:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262870, encodeId=f1ee2628e09f, content=所以缺啥补啥, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Mon Nov 20 16:17:09 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
    2017-11-22 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1655618, encodeId=c50d165561878, content=<a href='/topic/show?id=93e12218000' target=_blank style='color:#2F92EE;'>#中心血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22180, encryptionId=93e12218000, topicName=中心血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7724759256, createdName=Homburg, createdTime=Thu Dec 28 13:24:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275733, encodeId=ae422e5733d9, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 13:01:53 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356577, encodeId=0a4f13565e715, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 22 06:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562749, encodeId=97641562e49d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Nov 22 06:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262870, encodeId=f1ee2628e09f, content=所以缺啥补啥, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Mon Nov 20 16:17:09 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
    2017-11-22 slcumt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1655618, encodeId=c50d165561878, content=<a href='/topic/show?id=93e12218000' target=_blank style='color:#2F92EE;'>#中心血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22180, encryptionId=93e12218000, topicName=中心血压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d7724759256, createdName=Homburg, createdTime=Thu Dec 28 13:24:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275733, encodeId=ae422e5733d9, content=学习学习.继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Fri Jan 05 13:01:53 CST 2018, time=2018-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356577, encodeId=0a4f13565e715, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Nov 22 06:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562749, encodeId=97641562e49d5, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Nov 22 06:24:00 CST 2017, time=2017-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262870, encodeId=f1ee2628e09f, content=所以缺啥补啥, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/24/1c2dbd6706e64df33befd6663f1d6b37.jpg, createdBy=94f61661779, createdName=lyh994, createdTime=Mon Nov 20 16:17:09 CST 2017, time=2017-11-20, status=1, ipAttribution=)]
    2017-11-20 lyh994

    所以缺啥补啥

    0

相关资讯

Asia Pac Allergy:永久性过敏性鼻炎患者中,血清25-羟甲基维生素D与血嗜酸细胞负相关

维生素D和过敏性鼻炎(AR)之间的关系仍旧不清楚。最近,有研究人员通过在患有AR的病人中检测血清25-羟甲基维生素D(25(OH)D)调水平、血嗜酸细胞和维生素D受体(VDR)在鼻粘膜上的表达调查了它们之间的关系。研究包括了32名患有永久性过敏性鼻炎的病人和25名对照。研究人员通过酶联免疫试验检测了血清25(OH)D的水平,利用自动化的血液系统检测了外周血嗜酸细胞,然而在下鼻甲粘膜中VDR的表达则

Lancet Respir Med:维生素D能否降低低基线维生素D水平哮喘患者加重的发生率?

2017年10月,发表在《Lancet Respir Med》上的一项系统评价和Meta分析,研究了补充维生素D 能否降低低基线维生素D水平患者哮喘加重的发生率。研究结果表明:维生素D补充可降低需要全身糖皮质激素治疗的哮喘加重的总体发生率。但未找到明确证据表明,该干预效果在各患者亚组中具有差异。

JCEM:产前维生素D补充与胎儿生长有何关系!

从发展中国家的研究结果表明孕妇补充维生素D可以引起胎儿25(OH)D水平轻微但显著地升高,从而改善胎儿生长。

JCEM:补充维生素D对精液质量、生殖激素及出生率的影响!

由此可见,高剂量维生素D补充并不能改善维生素D缺乏的不育男性的精液质量。补充维生素D对少精症与维生素D缺乏男性出生率和血清抑制素B的积极影响可能具有临床意义,而且可能是通过其他途径起作用。

维生素D可能是增强烧伤愈合的简单疗法

根据哈罗盖特内分泌学会年会上的一项研究,维生素D水平较高的严重烧伤患者比较低水平的患者恢复的成功率更高。这项研究首次研究了维生素D在烧伤恢复中的作用,并提示补充维生素D可能是一种简单而有效的治疗烧伤愈合的方法。尽管在过去的10年中,烧伤护理有所改进,但仍有许多患者仍有恢复不良的危险。并发症的范围可以从伤口愈合延迟到感染。严重烧伤患者感染的风险很高,可能导致危及生命的败血症。众所周知,维生素D具有抗

化学药独霸百亿级骨质疏松药市场,OTC药物占**优势

近几年,我国骨质疏松药物市场呈持续上升趋势,化学药、OTC药物占绝对优势,内资企业在这一市场竞争力相对薄弱。国产药企增长迅猛,未来或将进一步发挥主场优势,而排名前10的产品之间差距并不明显,市场竞争激烈。